Fujifilm Holdings (TSE:4901) subsidiary Fujifilm Medical Systems said today it won an Authority to Operate from the US Department of Defense for its Synapse PACS line, touting it as the 1st such product to receive a risk management framework based ATO.
With the clearance, the US DoD has determined that the Synaps PACS line meets its RMF controls, including the DoD 8500 Series controls and the Security and Techinical Implementation Guide requirements. The clearance is valid until March 2020.
“This latest ATO from the Department of Defense is testimony to the fact that risk mitigation remains a top priority at Fujifilm. We look forward to our continued strong relationship with the DoD,” medical informatics VP Bill Lacy said in a prepared statement.
“This particular ATO is an unprecedented achievement in that our technology had to stand up to the rigors of a brand new risk management framework process recently implemented by the Department of Defense. The fact that Fujifilm is the very first vendor to meet these new challenges speaks to our unrivalled history of innovation, flexibility and stringent security standards,” COO Johann Fernando
said in a press release.
